Using ketone supplements to improve heart health in women with PCOS
Exogenous Ketone Supplementation to Improve Cardiovascular Disease Risk Factors in Females with Polycystic Ovary Syndrome
This study tests if taking ketone supplements can help improve heart health in women aged 18 to 40 who have polycystic ovary syndrome (PCOS).
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | All |
| Sponsor | McGill University Academic / other |
| Locations | 1 site (Montreal, Quebec) |
| Trial ID | NCT06155708 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of exogenous ketone monoester supplementation on cardiovascular health in females diagnosed with polycystic ovary syndrome (PCOS). PCOS is a common condition that can lead to serious cardiovascular issues due to insulin resistance and elevated blood pressure. The trial aims to determine whether ketone supplementation can improve markers of cardiovascular health in this population. Participants will be females aged 18 to 40 with a confirmed diagnosis of PCOS, and they will receive either ketone supplements or water as a control.
Who should consider this trial
Good fit: Ideal candidates for this study are females aged 18 to 40 who have been diagnosed with polycystic ovary syndrome.
Not a fit: Patients with overt cardiometabolic diseases, current pregnancy, or those on certain medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a novel dietary intervention to improve cardiovascular health in women with PCOS.
How similar studies have performed: While the use of ketone supplementation has shown promise in other populations, this specific application in PCOS is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All female participants will report female sex assigned at birth * All participants will be aged 18 to 40 * PCOS diagnosis Exclusion Criteria: * Current smokers or a prolonged history of smoking * Presence or history of overt cardiometabolic disease (e.g., stage 2 hypertension, diabetes, heart disease), neurologic disease, or endocrinopathy (with the exception of PCOS) * Current pregnancy or currently breastfeeding * Current use of medications which may affect our outcomes of interest (e.g., anti-hypertensives, anti-androgens, metformin)
Where this trial is running
Montreal, Quebec
- Cardiovascular Health and Autonomic Research Laboratory — Montreal, Quebec, Canada (Recruiting)
Study contacts
- Principal investigator: Charlotte Usselman, Ph.D — McGill University
- Study coordinator: Charlotte Usselman, Ph.D
- Email: charlotte.usselman@mcgill.ca
- Phone: 5143962140
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.